Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 3/20 | 0.40 |
| ▸ | HTR7 | P34969 | 3/20 | 0.40 |
| ▸ | HTR2C | P28335 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR5A | P47898 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30167242 | 1.00 | CYP19A1 (0.41) | CYP19A1CYP11B1CYP11B2ADRA2ACYP2D6 | |
| SCHEMBL1011370 | 0.81 | ALDH1A1 (0.47) | CYP19A1CYP11B1CYP11B2HTR1AHTR7 | |
| SCHEMBL28163806 | 0.78 | PARP1 (0.42) | CYP19A1CYP2D6HTR1AHTR7HTR2C | |
| SCHEMBL1009344 | 0.78 | CYP19A1 (0.41) | CYP19A1CYP11B1CYP11B2HTR1AHTR7 | |
| SCHEMBL15487682 | 0.78 | KDM4E (0.40) | CYP2D6HTR1AHTR7HTR2CKDM4E | |
| SCHEMBL29607356 | 0.78 | PARP10 (0.42) | CYP2D6HTR1AHTR7HTR2CKDM4E | |
| SCHEMBL1011067 | 0.78 | PARP10 (0.42) | CYP2D6HTR1AHTR7HTR2CKDM4E | |
| SCHEMBL28164453 | 0.78 | PARP1 (0.42) | CYP2D6HTR1AHTR7HTR2CKDM4E | |
| SCHEMBL11259543 | 0.77 | MAPK10 (0.42) | HTR1AHTR7MAPK10MAPK14 | |
| SCHEMBL1011242 | 0.75 | HTR2C (0.55) | CYP19A1HTR2CKDM4EMAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115650824-B | Chiral diol and preparation method thereof, prepared catalyst and preparation method and application thereof | 合肥工业大学 | 2024-01-23 | — | — | CN | claimed |
| CN-115650824-B | Chiral diol and preparation method thereof, prepared catalyst and preparation method and application thereof | 合肥工业大学 | 2024-01-23 | — | — | CN | disclosed |
| CN-115650824-A | Chiral diol and preparation method thereof, prepared catalyst, preparation method and application | 合肥工业大学 | 2023-01-31 | — | — | CN | disclosed |
| EP-2888259-B1 | DIAZEPINONE DERIVATIVES USEFUL FOR THE TREATMENT OF FRAGILE X SYNDROME, PARKINSONS OR REFLUX DISEASE | NOVARTIS AG (CH) | 2018-03-07 | — | — | EP | disclosed |
| US-20170305903-A1 | DIAZEPINONE DERIVATIVES | NOVARTIS AG (CH) | 2017-10-26 | — | — | US | disclosed |
| US-9650377-B2 | Diazepinone derivatives | NOVARTIS AG (CH) | 2017-05-16 | — | — | US | disclosed |
| US-20160159795-A1 | DIAZEPINONE DERIVATIVES | NOVARTIS AG (CH) | 2016-06-09 | — | — | US | disclosed |
| US-9284331-B2 | Diazepinone derivatives | NOVARTIS AG (CH) | 2016-03-15 | — | — | US | disclosed |
| EP-2888259-A1 | DIAZEPINONE DERIVATIVES USEFUL FOR THE TREATMENT OF FRAGILE X SYNDROME, PARKINSONS OR REFLUX DISEASE | Novartis AG (CH) | 2015-07-01 | — | — | EP | disclosed |
| US-20140357625-A1 | DIAZEPINONE DERIVATIVES | NOVARTIS AG (CH) | 2014-12-04 | — | — | US | disclosed |
| EP-2090576-A1 | 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators | Merz Pharma GmbH & Co.KGaA (DE) | 2009-08-19 | — | — | EP | disclosed |
| EP-2090576-A1 | 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators | Merz Pharma GmbH & Co.KGaA (DE) | 2009-08-19 | — | — | EP | disclosed |
| WO-2009095253-A1 | 6-HALO-PYRAZOLO[1, 5-A]PYRIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR (MGLUR) MODULATORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2009-08-06 | — | — | WO | disclosed |
| CN-101501036-A | Substituted pyrazolopyrimidines, a process for their preparation and their use as medicine | MERZ PHARMA GMBH & CO KGAA (DE) | 2009-08-05 | — | — | CN | disclosed |
| EP-2054416-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE | Merz Pharma GmbH & Co. KGaA (DE) | 2009-05-06 | — | — | EP | disclosed |
| US-20080039458-A1 | Substituted pyrazolopyrimidines, a process for their preparation and their use as medicine | MERZ PHARMA GMBH & CO. KGAA (DE) | 2008-02-14 | — | — | US | disclosed |
| US-20080039458-A1 | Substituted pyrazolopyrimidines, a process for their preparation and their use as medicine | MERZ PHARMA GMBH & CO. KGAA (DE) | 2008-02-14 | — | — | US | disclosed |
| US-20080039458-A1 | Substituted pyrazolopyrimidines, a process for their preparation and their use as medicine | MERZ PHARMA GMBH & CO. KGAA (DE) | 2008-02-14 | — | — | US | disclosed |
| WO-2008015269-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE | MERZ PHARMA GMBH & CO. KGAA (DE) | 2008-02-07 | — | — | WO | disclosed |
| WO-2008015269-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE | MERZ PHARMA GMBH & CO. KGAA (DE) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160159795-A1 | DIAZEPINONE DERIVATIVES | ADRB1, ADRB2, BRD4 | CYP19A1 1328/4885CYP11B1 25/4885CYP11B2 13/4885 |
| US-20080039458-A1 | Substituted pyrazolopyrimidines, a process for their preparation and their use as medicine | GRM5, GRM1, GRM3 | CYP19A1 3535/4885CYP11B1 271/4885CYP11B2 247/4885 |
| US-20170305903-A1 | DIAZEPINONE DERIVATIVES | ADRB1, ADRB2, BRD4 | CYP19A1 1328/4885CYP11B1 25/4885CYP11B2 13/4885 |
| US-20140357625-A1 | DIAZEPINONE DERIVATIVES | ADRB1, ADRB2, BRD4 | CYP19A1 1328/4885CYP11B1 25/4885CYP11B2 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.